Edgewise Therapeutics (EWTX) Common Equity (2020 - 2026)
Edgewise Therapeutics (EWTX) posted Common Equity of $493.2 million for Q1 2026, down 5.56% sequentially from $522.3 million in Q4 2025, and up 14.77% YoY from $429.7 million in Q1 2025.
Edgewise Therapeutics (EWTX) Common Equity (2020 - 2026) Analysis & Trends
Edgewise Therapeutics has reported Common Equity for 7 years, with the latest figure at $493.2 million in Q1 2026.
- Quarterly Common Equity rose 14.77% year-over-year to $493.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $493.2 million (up 14.77% YoY) and the FY2025 annual result came in at $522.3 million, up 13.73% from the prior year.
- Common Equity eased to $493.2 million in Q1 2026 per EWTX's latest filing, from $522.3 million in the prior quarter.
- Over five years, Common Equity peaked at $589.1 million in Q2 2025 and troughed at $246.4 million in Q2 2022.
- A 5-year average of $414.8 million and a median of $429.7 million in 2025 frame the typical range for Common Equity.
- The sharpest annual moves came in 2024 and 2025: Common Equity surged 68.33% in 2024, then dropped 19.67% in 2025.
- Over 5 years, Common Equity stood at $346.7 million in 2022, then fell by 8.04% to $318.8 million in 2023, then surged by 44.03% to $459.2 million in 2024, then climbed by 13.73% to $522.3 million in 2025, then declined by 5.56% to $493.2 million in 2026.
- According to Business Quant data, Common Equity over the past three periods registered $493.2 million, $522.3 million, and $558.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Edgewise Therapeutics | 4.76 Bn | 4.76 Bn | - | 448.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 448.08 Mn |
| Mar 31, 2026 | 493.20 Mn |
| Dec 31, 2025 | 522.26 Mn |
| Sep 30, 2025 | 558.65 Mn |
| Jun 30, 2025 | 589.07 Mn |
| Mar 31, 2025 | 429.72 Mn |
| Dec 31, 2024 | 459.22 Mn |
| Sep 30, 2024 | 488.88 Mn |
| Jun 30, 2024 | 510.47 Mn |
| Mar 31, 2024 | 534.94 Mn |
| Dec 31, 2023 | 318.83 Mn |
| Sep 30, 2023 | 290.43 Mn |
| Jun 30, 2023 | 311.46 Mn |
| Mar 31, 2023 | 328.84 Mn |
| Dec 31, 2022 | 346.72 Mn |
| Sep 30, 2022 | 361.40 Mn |
| Jun 30, 2022 | 246.36 Mn |
| Mar 31, 2022 | 260.36 Mn |
| Dec 31, 2021 | 274.38 Mn |
| Sep 30, 2021 | 285.40 Mn |